<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <Volume-Issue>Volume 2; Issue 3</Volume-Issue>
      <Season>(May-Jun, 2021)</Season>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Are There Differences in Potency Between SGLT-2 Receptor Blockers Utilized in The Therapy of Heart Failure?</ArticleTitle>
      <Abstract>SGLT-2 inhibitors are equally efficacious in lowering glucose levels. However, it is not known whether this is the case in the therapy of heart failure. We describe a case in a single patient where biomarkers of heart failure were not equally lowered by three different SGLT-2s. We conclude that while in the therapy of diabetes SGLT-2s are interchangeable this may not be true with heart failure therapy.</Abstract>
      <Keywords>Heart failure,Dapaglifozin,Canagliflozin,Empagliflozin,Amputation</Keywords>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=9598&amp;title=Are There Differences in Potency Between SGLT-2 Receptor Blockers Utilized in The Therapy of Heart Failure?</Abstract>
        <References>Bell DSH and Goncalves E. Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. Diabetes Obes Metab 2019; 21: 1277-1290.&#13;
Bell DSH and Goncalves E. Increase in glycated haemoglobin concentrations after unwarranted prescription changes. Diabetes Obes Metab 2018; 20: 2510-2511.&#13;
Blonde L, Patel C, Bookhart B, Pfeifer M, Chen YW, Wu B. A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin. Curr Med Res Opin 2018; 34: 1143-1152.&#13;
Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016; 37: 1526-1534.&#13;
Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies MJ. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults with Type 2 Diabetes. J Am Coll Cardiol 2017; 70: 704-712.&#13;
McMurray JJV, Solomon SD, Inzucchi SE, Kand;oslash;ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B?lohland;aacute;vek J, Band;ouml;hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukand;aacute;t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, Oand;#39;Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjand;ouml;strand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381: 1995-2008.&#13;
Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, Drazner MH, Fong MW, Givertz MM, Gordon RA, Jermyn R, Katz SD, Lamba S, Lanfear DE, LaRue SJ, Lindenfeld J, Malone M, Margulies K, Mentz RJ, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation 2019; 140: 1463-1476.&#13;
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306.&#13;
Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2014; 74: 807-824.&#13;
Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovasc Diabetol 2019; 18: 76.&#13;
Shi X, Verma S, Yun J, Brand-Arzamendi K, Singh KK, Liu X, Garg A, Quan A, Wen XY. Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? Mol Cell Biochem 2017; 433: 97-102.</References>